UK: +44 1379 658 721
Ireland: +353 89 221 3723
USA: +1 754 252 3536
Middle East - N. Africa: + 971 52 873 4738
Australia: +61 3 9310 5259
The latest stats, up to and including 3rd December 2022, saw a 12.2% rise in UK covid cases, a 24.8% drop in covid deaths, and an 11.7% rise in covid hospitalisations. There’s also some potential good news going forwards with a new drug that targets the body’s ACE2 receptors – there’s a decent chance it might also fight off new covid variants. Let’s see what’s going on out there.
Can a new drug protect us against new covid variants?
Current covid treatments and vaccines work against the virus itself, but they’re set to become less effective as it mutates to avoid immunity. Ursodeoxycholic acid (UDCA) has been approved for treating gallstones and liver conditions. It does so by inhibiting cells' ACE2 receptors, the same ones the covid spike protein attaches itself to, and it might also protect people against new covid variants.
The research into FXR, ACE2 and UDCA
A team at the University of Cambridge has discovered that a molecule called FXR regulates the activity of the ACE2 receptor. They’ve also proved previous research showing UDCA, in turn, regulates FXR.
Nine hamsters were given a human-level dose of UDCA and infected with the covid Delta variant a week later. Just 33% of them caught Delta, compared with all the hamsters in the control group who’d been given a saline solution instead of the UDCA. The hamsters given the saline solution had also lost far more weight four days after catching Delta, while the UDCA hamsters actually gained weight.
The results suggest that while UDCA won’t prevent the virus getting into cells, it reduces the amount of virus entering them as well as cutting down how much it replicates. And that could be very good news indeed in a world where more new variants aren’t an ‘if’ but a matter of ‘when’.
The same effect was noted when the drug was tested on a pair of human lungs intended to use in a transplant, which turned out to be unsuitable after all. Levels of ACE2 in the treated lung had roughly halved, while there was barely any change in the control lung.
The conclusion – Next comes human trials
It looks like a UDCA-like drug might be good for people with suppressed immune systems, whose immune response to vaccination isn’t very good. Some are already offered the drug Evusheld, whose antibodies bind to ACE2, where they stop covid getting a grip. Because ACE2 is the doorway through which covid gets into our bodies, closing the door means it can’t replicate itself. So it dies off without needing help from the immune system.
While UDCA will never replace vaccination, which remains the best way to stay safe, it could work together with vaccinations to keep people safer. The next step is human trials.
Disinfect your premises to help keep everyone well
Reduce the number of days people take off-sick. Keep your employees healthier – and by doing so help them to protect the vulnerable people in their families. Play your part in keeping covid and other diseases at bay so there’s less risk of dangerous variants arising. And do it all at a surprisingly low cost with our brilliantly effective, easy-to-fit, maintenance free lamps, units and sterilisers.